Search results
Apr 25, 2024 · SAN ANTONIO, April 24, 2024 /PRNewswire/ -- Summit Clinical Research, LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and ...
Apr 25, 2024 · SAN ANTONIO, April 25, 2024 /PRNewswire/ -- Pinnacle Clinical Research, LLC ("Pinnacle") is deeply saddened by the death of Founder and Chairman Dr. Stephen Harrison. Pinnacle mourns Dr. Harrison ...
May 3, 2024 · Internationally recognized for his research and treatment of nonalcoholic fatty liver disease (NAFLD), later named metabolic dysfunction-associated steatotic liver disease (MASLD), Dr. Harrison leaves behind a legacy of unparalleled excellence in liver research and patient advocacy.
Apr 25, 2024 · In Memoriam: A Catalyst for Medical Advancements: As we reflect on the legacy of Dr. Stephen Harrison, his impact on the field of medicine is undeniable. This visionary scientist revolutionized medical research and his contributions will forever be etched in the annals of scientific achievements.
Apr 25, 2024 · Harrison, who dedicated his illustrious 30-year career to liver research, played a pioneering role in advancing the understanding and treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Apr 25, 2024 · SAN ANTONIO, April 24, 2024 /PRNewswire/ — Summit Clinical Research LLC (“Summit”) is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones. During an illustrious 30-year ...
May 7, 2024 · Professor Harrison was a stalwart of hepatology. He led the way in the conduct of many clinical trials that recently culminated in the development of the first approved treatment for people with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD), a disease of pandemic proportions.
